PubMed Health⌕ Search

Biomedical subjects

J Germouty

Publications and source records attributed to J Germouty.

At least 19 recordsLinked to original sources
PubMed1992

[Long-term tolerability of formoterol in chronic obstructive bronchopathies].

Formoterol aerosol, a long-acting new beta 2-mimetic was administered over a year at a dose of 12 micrograms twice daily, to 62 chronic obstructive bronchitics of mean age 66 +/- 6 years and of whom the basal VEMS was at 12,801 +/- 0.59. Clinical tolerance of the product was good with undesirable effects in 13 patients, the most frequent being shaking. No untoward effect was seen on systolic or diastolic arterial pressure, or the heart rate over successive visits at 1, 3, 6, 9 months and one year. Electrocardiographic surveillance found in only four patients electrical abnormalities that may be due to Formoterol, these were patients without previous cardiac problems but of advanced mean age. Functionally, a significant improvement of basal VEMS was noticed from the 6th month. The VEMS improved significantly after administration of 12 micrograms on successive visits, without tachyphylactic signs. Well tolerated, with functional benefits, Formoterol is a promising product amongst the long-acting beta 2-mimetics. Its usefulness and limitations in the basic treatment of these chronic bronchopathies remains to be defined.

Adrenergic beta-Agonists↗
PubMed1992

[The influence of a new beta agonist: formoterol on mucociliary function].

The muco-ciliary apparatus has an essential role in the cleansing of the tracheo-bronchial tree of particulate matter. Disturbances linked to muco-ciliary function are well known in respiratory pathology and in cases of chronic bronchitis and asthma and lead to a reduced capacity for cleansing. In addition there are numerous pharmacological agents including sympathomimetics which are capable of altering the ciliary activity and the rheological properties of mucous. The role of Formoterol, administered as an aerosol has been assessed in vivo in 10 bronchitic patients who were in a stable state. After 6 days of treatment using the Formoterol aerosol the muco-ciliary clearance had significantly increased to 46% and was a real gain when compared to the muco-ciliary clearance measured on placebo. This gain was linked to a better function of the muco-ciliary carpet and not due to the bronchodilatation which was induced by Formoterol, because the penetration index did not change. At the same time the airway resistance was slightly reduced in a none significant fashion.

Administration, Inhalation↗
PubMed1991

[Clear cell tumor of the lung (sugar tumour). Study of a case].

A case of benign clear cell tumor ("sugar tumor") is reported. Light microscopy showed a proliferation of clear cells with a rich blood supply and endocrinoid pattern. Ultrastructurally, cells were loaded with glycogen both free and membrane-bound. The cellular origin of the benign clear cell tumor of the lung is still uncertain.

Adenocarcinoma↗
PubMed1989

Evaluation of the efficacy and safety of loratadine in perennial allergic rhinitis.

Loratadine, a new nonsedating antihistamine, was evaluated for efficacy and safety in 228 patients with perennial allergic rhinitis. Taken at a dose of 10 mg once daily, loratadine was significantly more effective than placebo and comparable to terfenadine, 60 mg taken twice daily, in reducing combined symptom scores in this patient population. Efficacy was maintained throughout the 28-day course of treatment. The overall incidence of side effects with loratadine was low (14%) with few occurrences of sedation (3%) and dry mouth (4%).

Adolescent↗
PubMed1989

[Post-traumatic pulmonary hematomas. Apropos of 2 cases].

Post-traumatic pulmonary hematoma presents clinically as a hemorrhagic collection within a newly-formed cavity in the lung parenchyma. Its frequency is probably underestimated in view of the importance of the associated lesions. The most frequent clinical sign is hemoptysis. The chest radiograph, as well as the CT scan, shows a clearly defined round image. As a rule, there is a favorable outcome with slow resorption over several weeks, with a restoration of the integrity of the pulmonary parenchyma, which justifies simple observation, with an absence of any therapeutic intervention.

Adult↗
PubMed1988

[Does extrinsic asthma exist?].

Asthma cannot be triggered exclusively by external causes, even allergy. For it to develop, the subject must have pathological bronchial hyper-reactivity. On the contrary, however, asthma cannot be explained solely by intrinsic causes, metabolic or endocrine. It persists only in those subjects who have bronchial hyper-reactivity. The authors suggest a new definition of asthma, designed to replace the semi-logical definition of Charpin: Asthma is a dyspnoeic bronchospasmodic crisis that is linked with the existence of pathological bronchial hyper-reactivity.

Asthma↗
PubMed1987

Clinical efficacy of ambroxol in the treatment of bronchial stasis. Clinical trial in 120 patients at two different doses.

Mucosolvan is a 'mucus-modifier' whose active compound is ambroxol. The aim of our research was to determine its clinical efficacy in the treatment of bronchial stasis by carrying out two successive double-blind studies in two parallel groups of patients and comparing ambroxol with placebo in a treatment lasting 10 days. The first trial involving 60 patients daily treated with 120 mg of ambroxol showed significant differences (p less than 0.05) in sputum volume, sputum viscosity, difficulty of expectoration, and severity of cough when compared with the placebo group. The two groups of patients were initially well matched and the drug was well tolerated. In a second trial involving 60 new patients daily treated with 30 mg of ambroxol, the drug showed no clear clinical effects. We conclude that ambroxol is an effective 'mucus modifier' and is well tolerated at a dose of 120 mg/day.

Adult↗
PubMed1987

[Prescription of Theostat 300 as a single evening dose].

Sixteen patients with asthma and/or chronic obstructive lung disease were treated for 8 days by scored tablets of sustained-release theophylline. Treatment was administered as a single evening dose per day, 2 hours after dinner, at a daily dosage of 10 mg/kg/day of theophylline. The theophylline curve remained in the theoretical therapeutic zone of 8 to 15 mcg/ml for about 14 hours; the clinical efficacy, evaluated on the basis of the improvement in the signs and symptoms, was satisfactory. The clinical acceptability was good apart from insomnia observed during the first 2 days of treatment.

Asthma↗
PubMed1986

Double-blind comparison of tulobuterol and salbutamol in chronic obstructive pulmonary disease.

A double-blind study compared tulobuterol (2 mg BID), a new beta 2-adrenergic agent, with salbutamol (2 mg TID) in 40 hospitalized men with chronic obstructive pulmonary disease. The study evaluated the bronchospasmolytic effects of the two drugs and their selectivity of action. Measurements and observations were made for six hours after the first oral dose, daily during nine days of continuous therapy, and for 12 hours after the final dose on the tenth day. Results show that the tulobuterol regimen produced a significant (P less than 0.01) improvement of the forced expiratory volume in one second equal to an increase of 25% above the pretreatment value, versus 16% with the salbutamol regimen. Cardiovascular effects appeared more rapidly with tulobuterol, but they stabilized to values lower than those observed with salbutamol. No clinically important adverse reactions were reported other than slight tremor, which was not objectionable.

Adrenergic beta-Agonists↗
PubMed1986

[Skin tests in the exploration of perianesthetic complications].

Adverse reactions in anesthesia are more and more frequent. The favoring factors are multiple but the physiopathology of these reactions are not right known: non specific histamine-release, complement activation is anaphylaxis can occur. Skin tests are an very important data for the diagnosis of these accidents. Forty patients and ten healthy subjects were tested with systematic research of a cross-reactivity for curare family; myorelaxants, fluid gelatin, dextran are the tests the most frequently positive. Cross reactivity for curare family is sure and sensibilization by some medicine is possible. Then the behavior of the data is looked at; the research of the favoring factors, the non utilization of some substances and prophylactic treatment are recommended.

Anesthetics↗
PubMed1986

[Immunotherapy of recurrent respiratory infections. Double-blind study of a new immunomodulator in 60 patients].

A new immunomodulator, SLO4 oral drops, was tested for treatment and prevention of recurrent respiratory infections in a double-blind, drug versus placebo trial conducted in 60 adults with chronic bronchitis or asthma. This agent brought about a highly significant reduction in the frequency and duration of infectious episodes, as well as a decrease in antibiotic consumption and lost work time. Well tolerated from the clinical and laboratory points of view, it proved remarkably effective. It has been hypothesized that induction of interferon may account for the excellent clinical results obtained with SLO4, and numerous authors regard this compound as one of the basic keys to regulation of immune reactivity. Pharmacological trials under way with SLO4 should help answer this question.

Adjuvants, Immunologic↗
PubMed1985

[Bronchopulmonary hamartochondroma (apropos of 136 cases, including a homogeneous series of 124 cases). Review of the literature].

On the basis of a series of 136 hamartochondromas, the largest ever published, the authors review the clinical and paraclinical characteristics of bronchopulmonary hamartochondromas. After describing their pathological study, particular attention is paid to the controversial pathogenesis of these tumors before dealing with therapeutic aspects. Review of the literature.

Adolescent↗